SRR934910
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.454
- INTERFERON_GAMMA_RESPONSE+0.401
- COAGULATION+0.379
- INTERFERON_ALPHA_RESPONSE+0.378
- INFLAMMATORY_RESPONSE+0.356
- KRAS_SIGNALING_DN+0.335
- IL6_JAK_STAT3_SIGNALING+0.298
- COMPLEMENT+0.198
- SPERMATOGENESIS+0.150
- TNFA_SIGNALING_VIA_NFKB+0.128
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.654
- MYC_TARGETS_V1-0.566
- PROTEIN_SECRETION-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.519
- NOTCH_SIGNALING-0.483
- ADIPOGENESIS-0.480
- MTORC1_SIGNALING-0.471
- MYC_TARGETS_V2-0.422
- DNA_REPAIR-0.421
- CHOLESTEROL_HOMEOSTASIS-0.417
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR603658 | GTEX | — | 0.934 |
| 2 | SRR1341057 | GTEX | — | 0.928 |
| 3 | SRR1395951 | GTEX | — | 0.926 |
| 4 | SRR1355373 | GTEX | — | 0.924 |
| 5 | SRR934916 | — | — | 0.918 |
| 6 | MNG450 | — | — | 0.917 |
| 7 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.916 |
| 8 | SRR1329835 | GTEX | — | 0.915 |
| 9 | SRR1473590 | GTEX | — | 0.914 |
| 10 | SRR1382869 | GTEX | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.454 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.401 | Idelalisib | — uncovered |
| COAGULATION | 0.379 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.378 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.356 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.335 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.298 | Inavolisib | — uncovered |
| COMPLEMENT | 0.198 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.128 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.105 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.091 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.085 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.011 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |